Predict your next investment

Venture Capital
atlasventure.com

See what CB Insights has to offer

Investments

794

Portfolio Exits

221

Funds

24

Partners & Customers

3

About Atlas Venture

Atlas Venture is an early stage venture capital firm investing in biotech innovation.

Atlas Venture Headquarter Location

25 First Street Suite 303

Cambridge, Massachusetts, 02141,

United States

617-588-2600

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Atlas Venture

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Atlas Venture in 2 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

382 items

C

CB Insights Healthcare Smart Money Investors - 2020

25 items

Track the world's top-performing VC investors in healthcare. Firms are presented in alphabetical order.

Latest Atlas Venture News

Sionna Therapeutics Raises $111M in Series B Financing

Apr 21, 2022

Sionna Therapeutics , a Boston, MA-based life sciences company developing differentiated treatments for cystic fibrosis (CF), closed a $111m Series B financing. The round was led by OrbiMed with participation from funds advised by T. Rowe Price Associates, Inc., Q Healthcare Holdings, LLC., a wholly owned subsidiary of QIA, the sovereign wealth fund of Qatar, and previous investors including RA Capital, TPG’s The Rise Fund, Atlas Venture, and the Cystic Fibrosis Foundation. The company, which has raised approximately $150m to date, intends to use the funds to advance development of a franchise of small molecules targeting NBD1 and complementary modulators, including NBD1’s interface with the intracellular loop 4 (ICL4) region and the transmembrane domain 1 (TMD1) of CFTR. Sionna plans to submit Investigational New Drug applications (IND) for its first NBD1 targeted program, SION-638, and for its lead ICL4 program, SION-109, within the next 12 months. Led by Mike Cloonan, President and Chief Executive Officer, Charlotte McKee, M.D., Chief Medical Officer, John Macor, Ph.D., Chief Scientific Officer, Elena Ridloff, Chief Financial Officer, Greg Hurlbut, Ph.D., Co-founder, Senior Vice President, Discovery Research, and Mark Munson, Ph.D., Co-founder, Vice President, Medicinal Chemistry, Sionna Therapeutics is a life sciences company dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. The company is advancing a pipeline of first-in-class small molecules designed to fully restore the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein that is defective in CF, by stabilizing CFTR’s first nucleotide-binding domain (NBD1). The company’s Board of Directors includes: Josh Resnick, M.D., Chair, Managing Director, RA Capital Bruce Booth, D.Phil., Partner, Atlas Venture Mike Cloonan, President & CEO, Sionna Therapeutics Lucian Iancovici, M.D., Managing Director, TPG Life Sciences Innovation Adam Rosenberg, J.D., Venture Partner, RA Capital Peter Thompson, M.D., Partner, OrbiMed FinSMEs 21/04/2022

Atlas Venture Investments

794 Investments

Atlas Venture has made 794 investments. Their latest investment was in Sionna Therapeutics as part of their Series B on April 4, 2022.

CBI Logo

Atlas Venture Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/19/2022

Series B

Sionna Therapeutics

$111M

Yes

4

4/14/2022

Series B

Be Biopharma

$130M

No

2

2/16/2022

Series B

Third Harmonic Bio

$105M

No

15

2/10/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

1/5/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/19/2022

4/14/2022

2/16/2022

2/10/2022

1/5/2022

Round

Series B

Series B

Series B

Series B

Series B

Company

Sionna Therapeutics

Be Biopharma

Third Harmonic Bio

Subscribe to see more

Subscribe to see more

Amount

$111M

$130M

$105M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

2

15

10

10

Atlas Venture Portfolio Exits

221 Portfolio Exits

Atlas Venture has 221 portfolio exits. Their latest portfolio exit was Vigil Neuroscience on January 07, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/7/2022

IPO

7

12/15/2021

Acquired

2

11/5/2021

IPO

6

10/22/2021

IPO

Subscribe to see more

Subscribe to see more

10

8/6/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/7/2022

12/15/2021

11/5/2021

10/22/2021

8/6/2021

Exit

IPO

Acquired

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

7

2

6

10

10

Atlas Venture Acquisitions

2 Acquisitions

Atlas Venture acquired 2 companies. Their latest acquisition was NovusPharma on September 20, 1999.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/20/1999

Convertible Note

$99M

Management Buyout

1

5/27/1993

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/20/1999

5/27/1993

Investment Stage

Convertible Note

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

Note

Management Buyout

Subscribe to see more

Sources

1

10

Atlas Venture Fund History

24 Fund Histories

Atlas Venture has 24 funds, including Atlas Venture Fund XIII.

Closing Date

Fund

Fund Type

Status

Amount

Sources

3/3/2022

Atlas Venture Fund XIII

$450M

1

7/6/2020

Accomplice Fortuity Pool

$110M

1

6/5/2020

Atlas Venture Fund XII

$400M

2

5/6/2020

Pride Fund

$99M

10

1/2/2019

Atlas Venture Opportunity Fund I

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

3/3/2022

7/6/2020

6/5/2020

5/6/2020

1/2/2019

Fund

Atlas Venture Fund XIII

Accomplice Fortuity Pool

Atlas Venture Fund XII

Pride Fund

Atlas Venture Opportunity Fund I

Fund Type

Subscribe to see more

Status

Subscribe to see more

Amount

$450M

$110M

$400M

$99M

$99M

Sources

1

1

2

10

10

Atlas Venture Partners & Customers

3 Partners and customers

Atlas Venture has 3 strategic partners and customers. Atlas Venture recently partnered with Caribou Biosciences on November 11, 2014.

Date

Type

Business Partner

Country

News Snippet

Sources

11/18/2014

Partner

United States

Caribou Biosciences Announces Co-Founding of Intellia Therapeutics

`` Caribou Biosciences is an ideal partner for Intellia Therapeutics as we seek to rapidly advance new therapies into the clinic , while further developing the technology to realize its full potential for a wide range of patient needs . ''

1

3/17/2014

Partner

United States

Subscribe to see more

Subscribe to see more

10

12/15/2011

Partner

Ireland

Subscribe to see more

Subscribe to see more

10

Date

11/18/2014

3/17/2014

12/15/2011

Type

Partner

Partner

Partner

Business Partner

Country

United States

United States

Ireland

News Snippet

Caribou Biosciences Announces Co-Founding of Intellia Therapeutics

`` Caribou Biosciences is an ideal partner for Intellia Therapeutics as we seek to rapidly advance new therapies into the clinic , while further developing the technology to realize its full potential for a wide range of patient needs . ''

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

Atlas Venture Team

25 Team Members

Atlas Venture has 25 team members, including current Chief Financial Officer, Ommer Chohan.

Name

Work History

Title

Status

Ommer Chohan

Chief Financial Officer

Current

Michael Forkel

Controller

Current

Diana Mac

Controller

Current

David Grayzel

Managing Director

Current

Jodie Morrison

General Partner

Current

Name

Ommer Chohan

Michael Forkel

Diana Mac

David Grayzel

Jodie Morrison

Work History

Title

Chief Financial Officer

Controller

Controller

Managing Director

General Partner

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.